Concentration of Management Resources on Boron Drugs for BNCT
First written in FY2021. 3 of 15 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Annual update of R&D expenditureAnnual report
「The company is a so-called biotech venture and concentrates its management resources on expanding BNCT indications and its development pipeline. R&D expenses for the fiscal year amounted to ¥301.914 million.」
The company maintained its concentration of resources on expanding BNCT indications and its development pipeline and reported annual R&D expenses of ¥301.914 million. - FY2026-H1Update on interim R&D spendingAnnual report
「R&D expenses for the interim accounting period amounted to ¥131.416 million. There were no material changes in the status of the company's R&D activities during the interim accounting period.」
The company maintained its concentration of R&D resources on expanding BNCT indications and its development pipeline and reported interim R&D expenses of ¥131.416 million. - FY2025Annual update of R&D expenditureAnnual report
「The company is a so-called biotech venture and concentrates its management resources on expanding BNCT indications and its development pipeline. R&D expenses for the fiscal year amounted to ¥328.407 million.」
The company maintained its concentration of resources on expanding BNCT indications and its development pipeline and reported annual R&D expenses of ¥328.407 million. - FY2025-H1Update on interim R&D spendingAnnual report
「R&D expenses for the interim accounting period amounted to ¥136.234 million. There were no material changes in the status of the company's R&D activities during the interim accounting period.」
The company maintained its concentration of R&D resources on its pharmaceutical development business and reported R&D expenses of ¥136.234 million for the interim accounting period. - FY2024-Q3Updated third-quarter R&D expense resultsAnnual report
「R&D expenses for the first 3 quarters cumulative period amounted to ¥208.524 million. There were no material changes in the status of the company's R&D activities during the first 3 quarters cumulative period.」
The company maintained its concentration of R&D resources on its pharmaceutical development business and reported R&D expenses of ¥208.524 million for the first 3 quarters cumulative period. - FY2024-Q2Updated second-quarter R&D expense resultsAnnual report
「R&D expenses for the first half cumulative period amounted to ¥145 million. There were no material changes in the status of the company's R&D activities during the first half cumulative period.」
The company maintained its concentration of R&D resources on its pharmaceutical development business and reported R&D expenses of ¥145 million for the first half cumulative period. - FY2024-Q1Updated first-quarter R&D expense resultsAnnual report
「R&D expenses for the first quarter cumulative period amounted to ¥69.792 million. There were no material changes in the status of the company's R&D activities during the first quarter cumulative period.」
The company maintained its concentration of resources on its pharmaceutical development business and reported R&D expenses of ¥69.792 million for the first quarter cumulative period. - FY2023-Q3Updated third-quarter R&D expense resultsAnnual report
「R&D expenses for the first 3 quarters cumulative period amounted to ¥185.789 million. There were no material changes in the status of the company's R&D activities during the first 3 quarters cumulative period.」
The company indicated that there were no material changes in the status of its R&D activities centered on boron drugs for BNCT and reported R&D expenses of ¥185.789 million. - FY2023-Q2Update to half-year R&D expensesAnnual report
「R&D expenses for the first half cumulative period amounted to ¥119.863 million. There were no material changes in the status of the company's R&D activities during the first half cumulative period.」
The company indicated that there were no material changes in the status of its R&D activities centered on boron drugs for BNCT and reported R&D expenses of ¥119.863 million. - FY2023-Q1Updated quarterly R&D expense resultsAnnual report
「R&D expenses for the first quarter cumulative period amounted to ¥61.551 million. There were no material changes in the status of the company's R&D activities during the first quarter cumulative period.」
The company maintained its concentration of resources on R&D activities centered on boron drugs for BNCT and reported first-quarter R&D expenses of ¥61.551 million. - FY2022Annual update of R&D expenditureAnnual report
「The company is a so-called drug-discovery biotech venture and concentrates its management resources on developing boron drugs for BNCT. R&D expenses for the fiscal year amounted to ¥255.208 million.」
The company maintained its concentration of resources on boron drugs for BNCT and reported annual R&D expenses of ¥255.208 million. - FY2022-Q3RestatedAnnual report
「R&D expenses for the first 3 quarters cumulative period amounted to ¥181.192 million. There were no material changes in the status of the company's R&D activities during the first 3 quarters cumulative period.」
The company maintained its concentration of resources on its pharmaceutical development business and reported R&D expenses of ¥181.192 million for the first 3 quarters cumulative period. - FY2022-Q2RestatedAnnual report
「As the company has a single segment consisting solely of its pharmaceutical development business, segment information has been omitted. R&D expenses for the first half cumulative period amounted to ¥130.633 million.」
The company has a single segment consisting solely of its pharmaceutical development business and reported first-half R&D expenses of ¥130.633 million. - FY2022-Q1RestatedAnnual report
「As the company has a single segment consisting solely of its pharmaceutical development business, segment information has been omitted. R&D expenses for the first quarter cumulative period amounted to ¥53.046 million.」
The company has a single segment consisting solely of its pharmaceutical development business and reported first-quarter R&D expenses of ¥53.046 million. - FY2021First statedAnnual report
「The company is a so-called drug-discovery biotech venture and concentrates its management resources on developing boron drugs for BNCT. R&D expenses for the fiscal year amounted to ¥307.545 million.」
The company concentrates its R&D resources on boron drugs for BNCT as its sole pharmaceutical development business.